Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia.

Abstract

It is currently unknown whether immunosuppressive therapy or hematopoietic stem cell transplantation is the most appropriate treatment strategy for children with refractory cytopenia and normal karyotype or trisomy 8. We report on 31 children with hypoplastic refractory cytopenia treated with immunosuppressive therapy consisting of antithymocyte globulin and cyclosporine. At 6 months, 22 of 29 evaluable patients had a complete or partial response; a total of ten patients achieved a complete response at varying time points. Six patients subsequently received a transplant because of non-response, progression to advanced myelodysplastic syndrome or evolution of monosomy 7. Overall and failure-free survival rates at 3 years were 88% and 57%, respectively.

• Authors: Ayami Yoshimi, Irith Baumann, Monika Führer, Eva Bergsträsser, Ulrich Göbel, Karl-Walter Sykora, Thomas Klingebiel, Ute Gross-Wieltsch, Marry M van den Heuvel-Eibrink, Alexandra Fischer, Peter Nöllke, Charlotte Niemeyer
• Journal: Haematologica (Haematologica) Vol. 92 Issue 3 Pg. 397-400 (Mar 2007) ISSN: 1592-8721 [Electronic] Italy
• PMID: 17339190 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antilymphocyte Serum
• Immunosuppressive Agents
• Cyclosporine
• Prednisone

Topics

• Antilymphocyte Serum (therapeutic use)
• Blood Transfusion
• Child
• Combined Modality Therapy
• Cyclosporine (therapeutic use)
• Disease Progression
• Disease-Free Survival
• Hematopoietic Stem Cell Transplantation
• Humans
• Immunosuppressive Agents (therapeutic use)
• Kaplan-Meier Estimate
• Leukocyte Count
• Myelodysplastic Syndromes (drug therapy, genetics, mortality, surgery)
• Prednisone (therapeutic use)
• Prospective Studies
• Recurrence
• Remission Induction
• Statistics, Nonparametric
• T-Lymphocytes
• Treatment Outcome